Cellectar's Iopofosine Shows Strong Efficacy in BTK-Refractory WM…

Event summary

Cellectar presented Phase 2b CLOVER WaM subset data showing 87.5% ORR and 16-month median DOR in BTK-refractory WM patients.
Phase 3 confirmatory trial initiation and site selection underway, with first patient dosing expected in Q1 2027.
FDA accelerated approval application anticipated in H1 2027 based on mature CLOVER WaM dataset.
Subgroup analysis included 24 patients, 75% BTK-refractory, with 100% clinical benefit rate observed.

The big picture

Cellectar's data positions iopofosine as a potential breakthrough for WM patients who've exhausted BTK inhibitors, a growing population as resistance develops to existing therapies. The Phase 3 trial and accelerated approval path suggest Cellectar is moving toward a potential commercial launch within two years, though competition and reimbursement dynamics in rare hematologic cancers remain key variables.

What we're watching

Regulatory Pathway: Whether the FDA will accept the Phase 2 data for accelerated approval given the strong subset results.
Clinical Execution: The pace at which Cellectar can enroll and complete the Phase 3 trial to support full approval.
Commercial Strategy: How Cellectar positions iopofosine in the WM treatment landscape post-BTK failure.